Mary Schramke, Kevin Corcoran, Friedrich von Bohlen, Thure Etzold, Peter Willinger, Joseph Donahue, Michael Pellini, Norrie Russell, Bjrn Ekstrm, Tim Germann | GenomeWeb

Lynx Therapeutics has named Mary Schramke as acting CEO, effective Dec. 15. She succeeds Kevin Corcoran, Lynx’s current president, CEO, and director, who is leaving to pursue “another business opportunity,” according to the firm. Lynx shareholders will soon vote on an agreement to be acquired by Solexa, whose current CEO, John West, will take over the role of CEO of the combined company after the merger is completed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.